The Science Advisory Board

Lessons learned help the cell and gene therapy industry deliver products to patients
On the second day of the Cell & Gene Meeting on the Mesa, Betty Woo, PhD, vice president and general manager of cell and gene therapy (CGT) at Thermo Fisher Scientific, led a workshop titled "Industrialization of Cell Therapy Manufacturing -- Lessons Learned From Biologics." ScienceBoard.net caught up with Woo following the workshop. Read More

Salmonella shows promise as cancer therapy
Salmonella may be useful as a bacterial delivery vector for cancer therapy, according to research published October 21 in Nature Communications. Read More

How can the cell and gene therapy field industrialize collaboration?
Adlai Goldberg, the global life sciences digital, social, and commercial innovation leader at Ernst & Young, led a workshop on "Unlocking the Power of Collaboration to Fuel the Industry Transformation for Cell and Gene Therapies" at the 2021 Cell & Gene Meeting on the Mesa. Goldberg called on the cell and gene therapy industry to adopt a mindset of co-collaboration. Read More

5 takeaways from the Cell & Gene Meeting on the Mesa
In this final episode of our coverage from the 2021 Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine, ScienceBoard.net Editor-in-Chief, Samantha Black, PhD, discusses five takeaways from the event. Read More

FDA grants orphan drug designation to Intellia's NTLA-2001
The U.S. Food and Drug Administration has granted an orphan drug designation to Intellia Therapeutics' NTLA-2001 therapy for the treatment of transthyretin amyloidosis. Read More

Selecta and Genovis enter exclusive license agreement
Selecta Biosciences and Genovis have inked a strategic licensing agreement to advance a next-generation immunoglobulin G protease for use in gene therapy and certain autoimmune diseases. Read More

Early engagement with regulatory agencies is key to therapeutic development
Next-generation advanced therapies call for novel regulatory approaches, according to Mark Lane, PhD, vice president, development consulting and scientific affairs, of Biopharma Excellence by PharmaLex. Lane moderated a panel discussion titled "Innovative Regulatory Pathways for Next-Generation Treatments" at the 2021 Cell & Gene Meeting on the Mesa. Read More

New platform identifies best viral vectors for gene therapy
Researchers have developed a novel computational platform that identifies the best viral vector to deliver a gene therapy to its target. The technology, described October 19 in eLife, promises to speed development of adeno-associated virus-mediated gene therapies against vision loss and other disorders. Read More